Todd K. Rosengart, M.D., professor and chair of surgery was awarded an NIH-National Heart, Lung, and Blood Institute R01 grant for his research proposal, In Situ Cardiac Infarct Cellular Reprogramming. The award is for $681,002 each year for four years.
Dr. Rosengart is DeBakey-Bard Chair of Surgery at Baylor College of Medicine and Professor of Heart & Vascular Disease at Texas Heart Institute. An extensively published investigator, he is also editor of Seminars in Thoracic and Cardiovascular Surgery and member of the NIH Bioengineering, Technology, and Surgical Sciences study section.
As one of the pioneers in the field of gene therapy, with work beginning in the early 90's, he now leads a team of scientists engaged in the study of cardiac cellular reprogramming. He holds twelve patents, including those for methods to induce angiogenesis.
No Small Feat
NIH funding for surgical research in general has decreased over the past decade from $270 million in 2003 to $219 million in 20131. In particular, the cardiothoracic surgery application success rate for NIH grants has declined since 2003 and is now only 14 percent2.
Currently, there are estimated to be fewer than 20 cardiothoracic surgeons with NIH funding.
1 Am J Surg. 2015 Jun;209(6):1083-9.
2 J Thorac Cardiovasc Surg. 2008 Aug;136(2):392-7